Cancer: Drugs
(asked on 5th November 2015) - View Source
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government which drugs have been delisted from the Cancer Drugs Fund; how many patients are currently being treated with each drug; and what steps they are taking to develop a new system for prescribing each drug.
Details of the drugs removed from the national Cancer Drugs Fund (CDF) list following re-prioritisation are shown in tables 1 and 2. The latest version of the list is available on NHS England’s website at: www.england.nhs.uk/ourwork/pe/cdf/. A copy is attached.
Table 1: Confirmation of previously notified drugs and indications delisted on 12 March 2015 | |
Drug | Indication removed |
Aflibercept | 2nd line in combination with irinotecan-based combination chemotherapy for metastatic colorectal cancer |
Bendamustine | Treatment of patients with indolent non-Hodgkin’s lymphoma who are refractory to rituximab |
Bevacizumab | 1st line in combination with oxaliplatin–based combination chemotherapy for metastatic colorectal cancer |
Bevacizumab | 1st line in combination with irinotecan–based combination chemotherapy for metastatic colorectal cancer |
Bevacizumab | 1st line in combination with single agent fluoropyrimidine–based chemotherapy for metastatic colorectal cancer. |
Bevacizumab | In combination with carboplatin and gemcitabine chemotherapy for recurrent platinum sensitive ovarian cancer |
Bortezomib | Re-treatment in patients with relapsed myeloma |
Bortezomib | Treatment of patients with relapsed Waldenstrom’s macroglobulinaemia |
Bortezomib | Treatment of patients with relapsed mantle cell lymphoma |
Bosutinib | Treatment of blast phase chronic myeloid leukaemia |
Cetuximab | 2nd line in combination with irinotecan chemotherapy for metastatic colorectal cancer in patients with RAS wild type (non-mutated) tumours |
Dasatinib | Treatment of the lymphoid blast phase of chronic myeloid leukaemia |
Everolimus | Treatment of progressive unresectable or metastatic well differentiated neuroendocrine tumour of the pancreas |
Lapatinib | In combination with capecitabine chemotherapy for HER-2 receptor positive locally advanced or metastatic breast cancer |
Ofatumumab | Treatment of relapsed or refractory chronic lymphatic leukaemia |
Pazopanib | Treatment of previously treated metastatic non-adipocytic soft tissue sarcomas |
Pegylated liposomal doxorubicin | 1st or 2nd line chemotherapy of angiosarcoma |
Pegylated liposomal doxorubicin | Chemotherapy of primary malignant sarcomas of the heart and great vessels |
Source: National Cancer Drugs Fund List Ver 6.0 | |
Table 2: Confirmation of previously notified drugs and indications delisted on 4 November 2015 | |
Drug | Indication removed |
Albumin bound Paclitaxel | First line treatment of advanced adenocarcinoma of the pancreas in combination with Gemcitabine |
Bendamustine | 2nd or subsequent line treatment of chronic lymphatic leukaemia for patients whom fludarabine combination therapy is not a therapeutic option |
Bendamustine | 2nd and subsequent line of treatment of mantle cell lymphoma in patients who have not received previous Bendamustine |
Bevacizumab | Treatment of patients with triple negative metastatic breast cancer and/or prior Taxane therapy |
Bevacizumab | 2nd or 3rd line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received Bevacizumab |
Bosutinib | Treatment of chronic phase CML refractory to Nilotinib or Dasatinib |
Bosutinib | Treatment of accelerated phase CML refractory to Nilotinib or Dasatinib |
Bosutinib | Treatment of accelerated phase CML where there is significant intolerance to Dasatinib and Nilotinib. |
Cetuximab | 3rd and subsequent line treatment of metastatic colorectal cancer as a single agent |
Cetuximab | 3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176 |
Dasatinib | Treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy including Imatinib |
Everolimus | 2nd or 3rd line treatment of metastatic renal cell carcinoma where disease has progressed on or after treatment with VEGF-targeted therapy |
Lenalidomide | 2nd line treatment of multiple myeloma in patients who have contraindications to the use of Bortezomib |
Panitumumab | 3rd and subsequent line treatment of metastatic colorectal cancer as a single agent |
Panitumumab | 3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176 |
Pegylated Liposomal Doxorubicin | 2nd line treatment of Fibromatosis |
Peptide Receptor Radionucleotide Therapy (Lutetium177 Octreotate or Yttrium90 Octreotide/Octreotate) | Treatment of advanced neuro-endocrine tumours i.e. for pNETS after Sunitinib/chemotherapy, for mid-gut carcinoid, after octreotide/somatostatin therapies. |
Pomalidomide | Treatment of relapsed and refractory multiple myeloma in patients who have received at least 2 prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy |
Source: National Cancer Drugs Fund List Ver 6.0 | |
NHS England publishes information on the number of patient applications for particular drugs/indications contained on the national CDF list on a quarterly basis. This information also includes the number of applications approved through the individual CDF request process. The latest information isattached as it is too long to be included in this answer. It is also available at:
www.england.nhs.uk/ourwork/pe/cdf/ and a copy of this is also attached.
The Government is committed to the CDF and is working with NHS England and the National Institute for Health and Care Excellence on the future arrangements for the Fund.